The novel ruthenium - γ-linolenic complex [Ru2(aGLA) 4Cl] inhibits C6 rat glioma cell proliferation and induces changes in mitochondrial membrane potential, increased reactive oxygen species generation and apoptosis in vitro

Cell Biochemistry and Function

Volumn 28, Issue 1, 2010, Pages 15-23

  Ribeiro, Geise ^a   Benadiba, Marcel ^a   Silva, Denise De Oliveira ^a   Colquhoun, Alison ^a  

^a UNIVERSITY OF SÃO PAULO   (Brazil)

Author keywords

linolenic acid; Apoptosis; Glioma; Mitochondria; Ruthenium

Indexed keywords

FAT DROPLET; GAMMA LINOLENIC ACID; HOE 33342; REACTIVE OXYGEN METABOLITE; RUTHENIUM; RUTHENIUM DERIVATIVE; RUTHENIUM GAMMA LINOLENIC COMPLEX; UNCLASSIFIED DRUG;

ANIMAL CELL; ANTINEOPLASTIC ACTIVITY; APOPTOSIS; ARTICLE; CELL COUNT; CELL CYCLE; CELL NUCLEUS; CELL POPULATION; CELL PROLIFERATION; CELL VIABILITY; CONTROLLED STUDY; DRUG EXPOSURE; DRUG SYNTHESIS; FLUORESCENCE ACTIVATED CELL SORTING; GLIOMA; GLIOMA CELL; IN VITRO STUDY; MITOCHONDRIAL MEMBRANE POTENTIAL; NONHUMAN; PRIORITY JOURNAL; RAT;

ANIMALS; ANTINEOPLASTIC AGENTS; APOPTOSIS; BENZIMIDAZOLES; CELL LINE, TUMOR; CELL PROLIFERATION; FLOW CYTOMETRY; G1 PHASE; GAMMA-LINOLENIC ACID; GLIOMA; MEMBRANE POTENTIAL, MITOCHONDRIAL; ORGANOMETALLIC COMPOUNDS; OXAZINES; RATS; REACTIVE OXYGEN SPECIES; RUTHENIUM; SPECTROPHOTOMETRY, ATOMIC; STAINING AND LABELING;

RATTUS;

EID: 74049149382     PISSN: 02636484     EISSN: 10990844     Source Type: Journal    
DOI: 10.1002/cbf.1626     Document Type: Article

References (40)

1. Giese A, Bjerkvig R, Berens ME, Westphal M. Cost of migration: invasion of malignant gliomas and implications for treatment. J Clin Oncol 2003; 21: 1624-1636.
2. Maher EA, Furnari FB, Bachoo RM, et al. Malignant glioma: genetics and biology of a grave matter. Genes Dev 2001; 15: 1311-1333.
3. Ferguson S, Lesniak MS. Convection enhanced drug delivery of novel therapeutic agents to malignant brain tumors. Curr Drug Deliv 2007; 4(2): 169-180.
4. Wen PY, Kesari S, Drappatz J. Malignant gliomas: strategies to increase the effectiveness of targeted molecular treatment. Expert Rev Anticancer Ther 2006; 6(5): 733-754.
5. Jiang H, Alonso MM, Gomez-Manzano C, Piao Y, Fueyo J. Oncolytic viruses and DNA-repair machinery: overcoming chemoresistance of gliomas. Expert Rev Anticancer Ther 2006; 6(11): 1585-1592.
6. Kim L, Glantz M. Chemotherapeutic options for primary brain tumors. Curr Treat Options Oncol 2006; 7(6): 467-478.
7. Tuettenberg J, Friedel C, Vajkoczy P. Angiogenesis in malignant glioma-a target for antitumor therapy? Crit Rev Oncol Hematol 2006; 59(3): 181-193.
8. Begin ME, Ells G, Das UN, Horrobin DF. Differential killing of human carcinoma cells supplemented with n-3 and n-6 polyunsaturated fatty acids. J Natl Cancer Inst 1986; 77(5): 1053-1062.
9. Das UN. Essential fatty acids, lipid peroxidation and apoptosis. Prostaglandins Leukot Essent Fatty Acids 1999; 61(3): 157-163.
10. Naidu MR, Das UN, Kishan A. Intratumoral gamma-linoleic acid therapy of human gliomas. Prostaglandins Leukot Essent Fatty Acids 1992; 45(3): 181-184.
11. Das UN, Prasad VV, Reddy DR. Local application of gamma-linolenic acid in the treatment of human gliomas. Cancer Lett 1995; 94(2): 147-155.
12. Leaver HA, Wharton SB, Bell HS, Leaver-Yap IM, Whittle IR. Highly unsaturated fatty acid induced tumour regression in glioma pharmacodynamics and bioavailability of gamma linolenic acid in an implantation glioma model: effects on tumour biomass, apoptosis and neuronal tissue histology. Prostaglandins Leukot Essent Fatty Acids 2002; 67(5): 283-292.
13. Bakshi A, Mukherjee D, Bakshi A, Banerji AK, Das UN. Gamma-linolenic acid therapy of human gliomas. Nutrition 2003; 19(4): 305-309 Comment on: Nutrition. April; 19(4):386-388.
14. Leaver HA, Williams JR, Smith C, Whittle IR. Intracellular oxidation by human glioma cell populations: effect of arachidonic acid. Prostaglandins Leukot Essent Fatty Acids 2004; 70(5): 449-453.
15. Das UN. From bench to the clinic: gamma-linolenic acid therapy of human gliomas. Prostaglandins Leukot Essent Fatty Acids 2004; 70(6): 539-552.
16. Colquhoun A, Schumacher RI. Gamma-linolenic acid and eicosapentaenoic acid induce modifications in mitochondrial metabolism, reactive oxygen species generation, lipid peroxidation and apoptosis in Walker 256 rat carcinosarcoma cells. Biochim Biophys Acta 2001; 1533(3): 207-219.
17. Colquhoun A, Schumacher RI. Modifications in mitochondrial metabolism and ultrastructure and their relationship to tumour growth inhibition by gamma-linolenic acid. Mol Cell Biochem 2001; 218(1-2): 13-20.
18. Colquhoun A. Gamma-linolenic acid alters the composition of mitochondrial membrane subfractions, decreases outer mitochondrial membrane binding of hexokinase and alters carnitine palmitoyltransferase I properties in the Walker 256 rat tumour. Biochim Biophys Acta 2002; 1583(1): 74-84.
19. Ramos KL, Colquhoun A. Protective role of glucose-6-phosphate dehydrogenase activity in the metabolic response of C6 rat glioma cells to polyunsaturated fatty acid exposure. Glia 2003; 43(2): 149-166.
20. Vartak S, Robbins ME, Spector AA. Polyunsaturated fatty acids increase the sensitivity of 36B10 rat astrocytoma cells to radiation-induced cell kill. Lipids 1997; 32(3): 283-292.
21. Vartak S, McCaw R, Davis CS, Robbins ME, Spector AA. Gamma-linolenic acid (GLA) is cytotoxic to 36B10 malignant rat astrocytoma cells but not to 'normal' rat astrocytes. Br J Cancer 1998; 77(10): 1612-1620.
22. Benadiba M, Miyake JA, Colquhoun A. Gamma-linolenic acid alters Ku80, E2F1, and bax expression and induces micronucleus formation in C6 glioma cells in vitro. IUBMB Life 2009; 61(3): 244-251.
23. Wernyj RP, Morin PJ. Molecular mechanisms of platinum resistance: still searching for the Achilles' heel. Drug Resist Updat 2004; 7(4-5): 227-232.
24. Brabec V, Novakova O. DNA binding mode of ruthenium complexes and relationship to tumor cell toxicity. Drug Resist Updat 2006; 9(3): 111-122.
25. Djinovic V, Momcilovic M, Grguric-Sipka S, et al. Novel ruthenium complex K2[Ru(dmgly)Cl4].2H2O is toxic to C6 astrocytoma cell line, but not to primary rat astrocytes. J Inorg Biochem 2004; 98(12): 2168-2173.
26. Keppler BK, Lipponer K, Stenzel B, Kratz F. Metal Complexes in Cancer Chemotherapy. Keppler BK. (ed.). VCH: New York, 1993.
27. Andrade A, Namora SF, Woisky RG, et al. Synthesis and characterization of a diruthenium-ibuprofenate complex comparing its anti-inflammatory activity with that of a copper(II)-ibuprofenate complex. J Inorg Biochem 2000; 81: 23-27.
28. Aquino MAS. Recent developments in the synthesis and properties of diruthenium tetracarboxylates. Coord Chem Rev 2004; 248: 1025-1045.
29. Ribeiro G, Benadiba M, Colquhoun A, Silva DO. Diruthenium (II, III) complexes of ibuprofen, aspirin, naproxen and indomethacin nonsteroidal anti-inflammatory drugs: synthesis, characterization and their effects on tumor-cell proliferation. Polyhedron 2008; 27: 1131-1137.
30. Mitchell RW, Spencer A, Wilkinson G. Carboxylato-triphenylphosphine complexes of ruthenium, cationic triphenylphosphine complexes derived from them, and their behaviour as homogeneous hydrogenation catalysts for alkenes. J Chem Soc Dalton Trans 1973; 8: 846.
31. + complexes. Higher energy electronic excited states. Inorg Chem 1988; 27: 2501-2506.
32. + complexes. J Am Chem Soc 1979; 101: 5256-5267.
33. Clark RJH, Ferri LTH. Resonance Raman, excitation profile, and electronic structural studies of diruthenium tetracarboxylate complexes. Inorg Chem 1981; 20: 2759-2766.
34. Ahmed SU, Reddy KK, Swathy SL, et al. Enrichment of c-linolenic acid in the lipid extracted from Mucor zychae MTCC 5420. Food Res Int 2009; 42: 449-453.
35. Nyquist RA, Putzig CL, Leugers MA. Infrared and Raman Spectral Atlas of Inorganic Compounds and Organic Salts: Text and Explanations. (Vol. 1), Academic Press: San Diego, 1996.
36. Nakamoto K. Infrared and Raman Spectra of Inorganic and Coordination Compounds. Parts A and B, (5th edn), John Wiley & Sons, Inc: New York, 1997.
37. Brabec V. Nováková O.DNA binding mode of ruthenium complexes and relationship to tumor cell toxicity. Drug Resist Updat 2006; 9(3): 111-122.
38. Kapitza S, Jakupec MA, Uhl M, Keppler BK, Marian B. The heterocyclic ruthenium(III) complex KP1019 (FFC14A) causes DNA damage and oxidative stress in colorectal tumor cells. Cancer Lett 2005; 226(2): 115-121.
39. Zorzet S, Bergamo A, Cocchietto M, et al. Lack of In vitro cytotoxicity, associated to increased G(2)-M cell fraction and inhibition of matrigel invasion, may predict In vivo-selective antimetastasis activity of ruthenium complexes. J Pharmacol Exp Ther 2000; 295(3): 927-933.
40. Bergamo A, Sava G. Ruthenium complexes can target determinants of tumour malignancy. Dalton Trans 2007(13): 1267-1272.